Clinical research firm ICON's Q2 revenue rises 1.2%, beats analyst estimates
ICLR•Outlook and drivers
- ICON reaffirms 2026 revenue guidance of $7.85 billion to $8.15 billion.
- The company maintains its 2026 adjusted diluted EPS outlook of $10.00 to $11.00.
- ICON said second-half performance may vary due to pass-through activity.
CEO Barry Balfe said disciplined cost management offset anticipated operational headwinds.
He also said higher pass-through activity contributed to revenue and net bookings, while strong strategic wins and new customer acquisition supported the book-to-bill ratio.
Key figures and analyst view
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $2.06 bln | $2.006 bln (14 Analysts) |
| Q2 Adjusted EPS | Beat | $2.56 | $2.51 (14 Analysts) |
| Q2 Net Income | $72.58 mln | ||
| Q2 Adjusted EBITDA | Beat | $327.2 mln | $322.40 mln (12 Analysts) |
| Q2 Operating Income | Miss | $137.83 mln | $270.46 mln (11 Analysts) |
| Q2 Pretax Profit | Miss | $92.20 mln | $228.64 mln (10 Analysts) |
The current average analyst rating on the shares is buy, with 11 strong buy or buy, 6 , and 1 or .
